Benefit of adjuvant effect of a drug named dexmedetomidine given through nose during pituitary tumor resection surgeries
Phase 1
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Registration Number
- CTRI/2020/07/026600
- Lead Sponsor
- zma Begum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA physical status I and II,
Patients scheduled for mTNTS surgery,
Exclusion Criteria
ASA physical status III and IV,
BMI <18 and >30,
GCS <15,
Patients with uncontrolled hypertension,
Anticipated difficult airway
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the adjuvant effect of intranasal dexmedetomidine on nasal mucosal decongestion in patients undergoing mTNTS procedureTimepoint: Start of anesthesia to 2 hours in PAC
- Secondary Outcome Measures
Name Time Method To assess the adjuvant effect of intranasal dexmedetomdine on incidence of hypertensive surge episodes and requirement of esmolol for management of these episodes in patients undergoing mTNTS surgeryTimepoint: Start of anesthesia to cessation of anesthesia